Diabetes Patents (Class 514/6.9)
  • Patent number: 10729634
    Abstract: Sex hormone-binding globulin and/or any fragment thereof for use as a medicament, in particular for use in the treatment of obesity and hepatic steatosis. The invention also relates to the cosmetic use of the sex hormone-binding globulin and/or any fragment thereof for improving the bodily appearance of a mammal with subcutaneous fat herniated or accumulated within the fibrous connective tissue under the skin, in particular the cosmetic use is for cellulite.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: August 4, 2020
    Assignee: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA
    Inventors: David Martinez Selva, Rafael Simó Canonge, Cristina Hernández Pascual, Cristina Saez Lopez, Anna Barbosa Desongles
  • Patent number: 10689430
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Patent number: 10610538
    Abstract: The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein Ra, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: April 7, 2020
    Assignees: Katholieke Universiteit Leuven, Consejo Superior de Investigaciones Científicas - CSIC
    Inventors: Jan Balzarini, Dolores González Pacanowska, Luis Miguel Ruiz Pérez, Victor Castillo Acosta, Yasuhiro Igarashi
  • Patent number: 10596389
    Abstract: A process for heat treating biological tissue includes generating treatment radiation having a predetermined wavelength and average power. The treatment radiation is applied to biological tissue, such as retinal tissue, such that at least one treatment spot is formed on the biological tissue and the biological tissue is heat stimulated sufficiently to create a therapeutic effect without destroying the tissue.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Ojai Retinal Technology, LLC
    Inventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
  • Patent number: 10588965
    Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 17, 2020
    Assignee: N.V. Nutricia
    Inventors: Bernd Stahl, Alma Jildou Nauta, Johan Garssen, Eric Samain, Sophie Drouillard
  • Patent number: 10300084
    Abstract: The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 28, 2019
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Kylhammar, Goran Radegran
  • Patent number: 10288629
    Abstract: The present invention provides a method for measuring growth hormone level in a human or animal subject, including a method of assessing pituitary-related growth hormone deficiency in a human or animal subject, after macimorelin oral administration to the subject.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 14, 2019
    Assignee: Aeterna Zentaris, Inc.
    Inventors: Nicola Ammer, Gilbert Muller, Richard Sachse, Herbert Sindermann
  • Patent number: 10287581
    Abstract: The present invention relates to a new family of cell-penetrating peptides, comprising an amino acid sequence X1LX2RALWRLX3RX4LWRLX5X6X7X8, wherein X1 is beta-A or S, X2 is F or W, X3 is L, W, C or I, X4 is S, A, N or T, X5 is L or W, X6 is W or R, X7 is K or R, and X8 is A or none. These peptides exhibit high efficiency, low toxicity and a natural tropism for lung tissues, and can be used either in simple complex with the cargo to be vectorised, or in nanoparticles comprising two layers of cell-penetrating peptides around the cargo.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 14, 2019
    Assignee: AADIGEN, LLC
    Inventors: Gilles Divita, Karidia Konate, May Catherine Morris, Sebastien Deshayes
  • Patent number: 10285973
    Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: May 14, 2019
    Assignees: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
  • Patent number: 10138469
    Abstract: Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 27, 2018
    Assignees: Toagosei Co., Ltd., Keio University, National University Corporation Nagoya University
    Inventors: Tetsuhiko Yoshida, Nahoko Baileykobayashi, Mikio Niwa, Jun Kudo, Tomohiro Izumiyama, Makoto Sawada
  • Patent number: 10071098
    Abstract: The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex labialis or herpes esophagitis, in a subject. In certain embodiments, the compositions of the invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: September 11, 2018
    Assignee: Drexel University
    Inventors: Jane E. Clifford, William E. Donegan, Oleg Alekseev
  • Patent number: 10004700
    Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 26, 2018
    Inventor: Jugal K. Taneja
  • Patent number: 9987232
    Abstract: A pharmaceutical composition comprising a mixture of: (c) an active macromolecular principle; (d) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA) and analogs and derivatives thereof, or mixtures thereof; and (d) a biguanide or a pharmaceutically acceptable salt thereof, capable of increasing the solubility of the aromatic alcohol absorption enhancer in an aqueous medium, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active principle.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: June 5, 2018
    Assignee: Axcess Limited
    Inventor: Roger R. C. New
  • Patent number: 9963504
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: May 8, 2018
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Patent number: 9931379
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 3, 2018
    Assignees: The Research Foundation for The State University of New York, California Institute for Biomedical Research
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • Patent number: 9821030
    Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: November 21, 2017
    Assignee: RegeneRx Biopharmaceuticals, Inc.
    Inventors: David Crockford, Allan L. Goldstein
  • Patent number: 9808522
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Patent number: 9765119
    Abstract: The invention is directed to isomeric mixtures of cyclosporine analogs that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises greater than about 80 percent by weight of the E-isomer and less than about 20 percent by weight of the Z-isomer, based on the total weight of the mixture.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 19, 2017
    Assignee: Aurinia Pharmaceuticals Inc.
    Inventors: Selvaraj A. Naicker, Randall W Yatscoff, Robert T Foster
  • Patent number: 9561262
    Abstract: The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: February 7, 2017
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Lynne M. Georgopoulos, Susan Arnold
  • Patent number: 9556426
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 31, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Patent number: 9499867
    Abstract: This document features method related to variants in the Inverted Formin 2 (INF2) gene that are susceptibility to focal segmental glomerulosclerosis (FSGS). For example, methods of using such variants for risk assessment and for diagnosing and optimizing treatment of FSGS are provided.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: November 22, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Martin Pollak, Elizabeth J. Brown, Johannes Schlondorff
  • Patent number: 9492505
    Abstract: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: November 15, 2016
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Sergei Zolotukhin, Andres Acosta
  • Patent number: 9422349
    Abstract: The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: August 23, 2016
    Assignee: HANMI SCIENCE CO., LTD
    Inventors: Sung Youb Jung, Chang Ki Lim, Dae Hae Song, Sung Min Bae, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 9394342
    Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: July 19, 2016
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, Amy Sturmer, William Stern
  • Patent number: 9289500
    Abstract: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a disease or disorder in a subject.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 22, 2016
    Assignees: The Regents of the University of California, City of Hope
    Inventors: Zhibin Guan, Yoko Mullen, Sophia W. Liao
  • Patent number: 9272023
    Abstract: The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: March 1, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Ivo M. Francischetti, Robson de Queiroz Monteiro, Jose Marcos C. Ribeiro
  • Patent number: 9234886
    Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 12, 2016
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Robert McVie, John Glawe
  • Publication number: 20150147325
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150148290
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 28, 2015
    Inventors: Eric Marsault, Carl St-Louis
  • Publication number: 20150139904
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: University of Miami
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
  • Publication number: 20150141329
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 21, 2015
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • Patent number: 9034818
    Abstract: The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: May 19, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Christian Poulsen, Kasper Huus, Frantisek Hubalek, Dorte Bjerre Steensgaard, Svend Havelund
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150132321
    Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Charles K. Thodeti
  • Publication number: 20150133375
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 14, 2015
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20150133373
    Abstract: Formulations are provided that comprise compounds having inter alia good duration of action, high potency and/or convenient dosing regimens, and a permeation enhancer for transmucosal administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. The pharmaceutical compositions provided are suitable for methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
    Type: Application
    Filed: March 28, 2013
    Publication date: May 14, 2015
    Inventors: Steven Shijun Ren, Li Jin
  • Patent number: 9029321
    Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: May 12, 2015
    Assignee: Board of Regents of the University of Texas
    Inventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
  • Patent number: 9029325
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Patent number: 9029322
    Abstract: The present invention relates to a method for identifying a drug candidate for enhancing expression of p21cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21C?1/waf1. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21cip1/waf1 promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cip1/waf1.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 12, 2015
    Assignee: Cornell University
    Inventors: Rajiv R. Ratan, Brett C. Langley, Brian S. Ko
  • Patent number: 9029505
    Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 12, 2015
    Assignee: Phasebio Pharmaceuticals, Inc.
    Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
  • Publication number: 20150126438
    Abstract: The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP ?. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP ? and methods of identifying one or more agents that modulate the expression of a ChREBP ? target gene.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 7, 2015
    Inventors: Mark A. Herman, Barbara B. Kahn
  • Publication number: 20150126443
    Abstract: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: Tesfaye Biftu, Ann E. Weber
  • Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Publication number: 20150118287
    Abstract: In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient a
    Type: Application
    Filed: February 13, 2013
    Publication date: April 30, 2015
    Inventors: H. Kirk Hammond, Mei Hua Gao
  • Patent number: 9018163
    Abstract: This invention relates to PCIFl and its use as a target for the improvement of pancreatic islet ? cell mass and function in diabetes. Specifically, the invention relates to the use of compounds capable of modulating the expression or function of PClFl and their effect on the function of Pdx-1.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: April 28, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Doris Stoffers
  • Publication number: 20150111818
    Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Thomas R. Alessi, Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang
  • Publication number: 20150111821
    Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
  • Patent number: 9012398
    Abstract: This invention provides Exendin-4 compounds derivatized at a lysine 14 residue to give an acylated lysine, pharmaceutical compositions comprising such compounds, and the use of such compositions for treating diabetes.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: April 21, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas K. Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
  • Publication number: 20150104388
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: David H. COY, Jerome L. MADERDRUT, Min LI
  • Patent number: 9006175
    Abstract: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin in diabetics requiring basal insulin replacement are provided.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: April 14, 2015
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner